Terns Pharmaceuticals' (TERN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $5.50 target price on the stock. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q2 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.36) EPS, […]

Related Keywords

China , ,Bleakley Financial Group ,Securities Exchange Commission ,Vivo Opportunity Llc ,Institutional Trading Of Terns Pharmaceuticals ,Simplicity Solutions ,China Universal Asset Management Co ,Terns Pharmaceuticals ,Terns Pharmaceuticals Stock Performance ,Analyst Recommendations For Terns Pharmaceuticals ,Insider Transactions At Terns Pharmaceuticals ,News Ratings For Terns Pharmaceuticals Daily ,Terns Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Get Free Report ,Vivo Opportunity ,Exchange Commission ,Universal Asset Management ,Financial Group ,Pale Fire Capital ,Terns Pharmaceuticals Daily ,